Ireland - English - HPRA (Health Products Regulatory Authority)

astrazeneca uk limited - budesonide formoterol fumatrate dihydrate - powder for inhalation - 100/6 microgram

Ireland - English - HPRA (Health Products Regulatory Authority)

astrazeneca uk limited - budesonide formoterol fumatrate dihydrate - powder for inhalation - 200/6 microgram

Ireland - English - HPRA (Health Products Regulatory Authority)

astrazeneca uk limited - budesonide formoterol fumatrate dihydrate - powder for inhalation - 200/6 microgram

Ireland - English - HPRA (Health Products Regulatory Authority)

astrazeneca uk limited - budesonide formoterol fumatrate dihydrate - powder for inhalation - 100/6 microgram

Ireland - English - HPRA (Health Products Regulatory Authority)

astrazeneca uk limited - budesonide formoterol fumatrate dihydrate - powder for inhalation - 400/12 microgram

Ireland - English - HPRA (Health Products Regulatory Authority)

astrazeneca uk limited - budesonide formoterol fumatrate dihydrate - powder for inhalation - 400/12 microgram

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; hypromellose; macrogol 400 - metformin is indicated in the treatment of type 2 diabetes mellitus not satisfactorily controlled by diet, where the risk of lactic acidosis is minimised by excluding predisposing factors, especially impaired renal, hepatic or cardiovascular function. metformin may be used as initial therapy or in sulfonylurea failure, either alone or in combination with a sulfonylurea or as adjuvant therapy in insulin-dependent diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; hypromellose; macrogol 400 - metformin is indicated in the treatment of type 2 diabetes mellitus not satisfactorily controlled by diet, where the risk of lactic acidosis is minimised by excluding predisposing factors, especially impaired renal, hepatic or cardiovascular function. metformin may be used as initial therapy or in sulfonylurea failure, either alone or in combination with a sulfonylurea or as adjuvant therapy in insulin-dependent diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; hypromellose; macrogol 400 - metformin is indicated in the treatment of type 2 diabetes mellitus not satisfactorily controlled by diet, where the risk of lactic acidosis is minimised by excluding predisposing factors, especially impaired renal, hepatic or cardiovascular function. metformin may be used as initial therapy or in sulfonylurea failure, either alone or in combination with a sulfonylurea or as adjuvant therapy in insulin-dependent diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; hypromellose; macrogol 400 - metformin is indicated in the treatment of type 2 diabetes mellitus not satisfactorily controlled by diet, where the risk of lactic acidosis is minimised by excluding predisposing factors, especially impaired renal, hepatic or cardiovascular function. metformin may be used as initial therapy or in sulfonylurea failure, either alone or in combination with a sulfonylurea or as adjuvant therapy in insulin-dependent diabetes.